Promoted Content
Promoted Content

Find Novel Neurology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Oscine

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glial progenitor cell therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sana Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 30, 2020

            Details:

            The combination will integrate Oscine’s glial progenitor cell program and underlying technologies together with Sana’s broader platform and programs. Terms of the acquisition were not disclosed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cladribine

            Therapeutic Area: Neurology Product Name: CRD1

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Omega Funds

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing October 13, 2020

            Details:

            The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roach.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Topiramate

            Therapeutic Area: Neurology Product Name: ET-101

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in patients, two years old.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CRISPR based gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $415.0 million Upfront Cash: $15.0 million

            Deal Type: Collaboration October 06, 2020

            Details:

            Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need.

            Progreso y Salud Foundation

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SV40 vector based gene therapy

            Therapeutic Area: Neurology Product Name: SVec

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Amarna Therapeutics

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 25, 2020

            Details:

            The collaboration is a joint effort between the research group of the FPS at research institute Cabime and Amarna Therapeutics which aims to assess the efficacy of SVec in reducing the immune responses that trigger the damage and loss of myelin in animal models of MS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: BB106

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bexson Biomedical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            Details:

            The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Butorphanol,Azaperone,CAS 86347-15-1

            Therapeutic Area: Neurology Product Name: BAM Kit

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wedgewood Pharmacy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 10, 2020

            Details:

            ZooPharm’s BAM™ Kit includes a patented combination of Butorphanol tartrate, Azaperone tartrate, and Medetomidine hydrochloride that is used to immobilize a broad range of species.

            University College London

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AlbionVC

            Deal Size: $13.2 million Upfront Cash: Undisclosed

            Deal Type: Funding August 03, 2020

            Details:

            Funding is focused on UCL's clinical developments in the field of gene therapy for an undisclosed neurometabolic disorder, a gene therapy for epilepsy, and a cell therapy for glaucoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 17, 2020

            Details:

            Following initial efforts focused on multiple sclerosis (MS), PicnicHealth, Roche and Genentech recently expanded their collaboration to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Opioid based transdermal medications

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nutriband

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 16, 2020

            Details:

            With this acquisition Pocono plans to consolidate capabilities at both facilities to expand on enhancing revenue stream opportunities and in-house product development, specifically our abuse deterrent technology for opioid based transdermal medications.

            PharmaCompass